In8Bio (INAB) Operating Leases (2021 - 2026)

In8Bio has disclosed Operating Leases across 6 years of filings, most recently posting $1.1 million for Q2 2026.

• In Q2 2026, Operating Leases fell 45.03% year-over-year to $1.1 million; the TTM figure through Jun 2026 stood at $1.1 million (down 45.03% YoY), while the FY2025 annual figure was $1.6 million, down 49.38% from the prior year.
• Operating Leases came in at $1.1 million for Q2 2026 at In8Bio, down from $1.3 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $3.9 million in Q3 2022 to a low of $1.1 million in Q2 2026.
• Average Operating Leases over 5 years is $2.6 million, with a median of $3.0 million recorded in 2023.
• Year-over-year, Operating Leases surged 149.01% in 2023 and sank 53.41% in 2026.
• Over 5 years, Operating Leases stood at $3.7 million in 2022, then declined by 22.32% to $2.9 million in 2023, then climbed by 8.2% to $3.1 million in 2024, then tumbled by 49.38% to $1.6 million in 2025, then retreated by 27.83% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $1.1 million in Q2 2026, $1.3 million in Q1 2026, and $1.6 million in Q4 2025.